Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval

benzinga.com/news/fda/25/06/45891179/nuvation-bios-ibtrozi-for-ros1-positive-lung-cancer-wins-fda-approval

The U.S. Food and Drug Administration (FDA) on Wednesday approved Nuvation Bio Inc.’s (NASDAQ:NUVB) Ibtrozi (taletrectinib) for adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).
The FDA approval of Ibtrozi is supported by one of…

This story appeared on benzinga.com, 2025-06-11 18:31:15.
The Entire Business World on a Single Page. Free to Use →